Collegium Pharmaceutical, Inc.
COLLHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Jul 15, 2026
Scan Results
Daily timeframeCollegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The $1.19B market capitalization puts COLL squarely in small-cap range for its industry. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine for severe and persistent pain that requires an extended treatment period; Xtampza ER, an abuse-deterrent, extended-release, oral formulation of oxycodone for the management of pain severe enough to require daily; Nucynta ER and Nucynta IR, which are extended-release and immediate-release oral formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.
Market Cap
$1.19B
Beta
0.73
P/E (TTM)
17.83
P/E (Fwd)
4.89
EPS (TTM)
$2.06
EPS (Fwd)
$7.51
ROE
27.4%
ROA
7.6%
Cash
$421.8M
Total Debt
$929.7M
Free CF
$332.6M
52W Change
15.6%
Annual Financials
Cash vs Debt
On the balance sheet, COLL has $421.8M in cash with $929.7M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. The company generates $332.6M in free cash flow annually, which funds everything from R&D to shareholder returns without needing external financing. Return on equity stands at 27.4%, which is strong for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. An ROA of 7.6% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $463.9M (2022) to $780.6M (2025), reflecting a 68% increase over the period.
Investors considering Collegium Pharmaceutical, Inc. should weigh the typical risks associated with COLL's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Collegium Pharmaceutical, Inc.'s trajectory.